EUVIMEDEUVIMED entdecken
Leitlinie

Are the screening guidelines for branch duct intraductal papillary mucinous neoplasms cost‐effective in an Australian setting?

Timothy Lai iD, Nicholas Bull, Janindu Goonawardena, Luke Bradshaw iD, Adrian Fox, Sayed Hassen

ANZ Journal of Surgery · 2023

DOI: 10.1111/ans.18697 ↗

Kurz gefasst

Leitlinie in der Zeitschrift ANZ Journal of Surgery, 2023. Verfasst von Timothy Lai und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Upper GI and HPB Surgery, Eastern Health, Box Hill, Victoria, Australia. Hauptthemen laut MEDLINE: Pancreatic Intraductal Neoplasms, Pancreatic Neoplasms, Neoplasms, Cystic, Mucinous, and Serous, Cysts. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Backgrounds Intraductal papillary mucinous neoplasms (IPMN) are cystic neoplasms of the pancreatic ductal system. These incidental cystic lesions are increasingly found on radiological imaging and screened for malignant transformation. The Fukuoka consensus guidelines recommend screening with computed tomography, magnetic resonance imaging or endoscopic ultrasound. Branch duct IPMN (BD‐IPMN) have significantly lower malignancy and mortality rates compared to main duct IPMN. Our aim was to assess the cost‐effectiveness of guideline's recommendations for BD‐IPMN screening of cysts between 2 and 3 cm in an Australian context.

Methods

Markov model decision analysis was used to calculate the incremental cost‐effectiveness ratio (ICER) of screening. The ICER was compared to a willingness to pay (WTP) threshold of $50 000. We performed scenario analysis to examine the effect of cyst size and non‐linearity of malignancy rate on ICER. Probabilistic sensitivity analyses (PSA) were performed on our input parameters.

Results

Screening resulted in 586 quality adjusted life years gained and a net present value of $20 379 939, resulting in a base‐case ICER of $34 758. After scenario analysis for non‐linearity of malignancy rate the ICER increases to $64 555, which is above the WTP threshold. PSA indicates that ICER is most susceptible to the pre‐test malignancy rate.

Conclusion

This cost analysis demonstrates that screening of 2–3 cm BD‐IPMN according to current guidelines is unlikely to be cost‐effective in an Australian context. To determine the true ICER, a cost analysis on real‐world data is required.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic Intraductal NeoplasmsPancreatic NeoplasmsNeoplasms, Cystic, Mucinous, and SerousCystsCarcinoma, Pancreatic DuctalHumansCost-Benefit AnalysisAustraliaRetrospective Studies

Stichwörter der Autor:innen

BD-IPMNIPMNbranch ducthealth economicshepatopancreaticobiliary surgeryintraductal papillary mucinous neoplasms

Autor:innen und Institutionen

  • Department of Upper GI and HPB Surgery, Eastern Health, Box Hill, Victoria, Australia.

ORCID-Profile: Timothy Lai, Luke Bradshaw

Zitieren

APA

Lai, T., Bull, N., Goonawardena, J., Bradshaw, L., Fox, A., & Hassen, S. (2023). Are the screening guidelines for branch duct intraductal papillary mucinous neoplasms cost‐effective in an Australian setting?. ANZ Journal of Surgery. https://doi.org/10.1111/ans.18697

Vancouver

Lai T, Bull N, Goonawardena J, Bradshaw L, Fox A, Hassen S. Are the screening guidelines for branch duct intraductal papillary mucinous neoplasms cost‐effective in an Australian setting?. ANZ Journal of Surgery. 2023. doi:10.1111/ans.18697

BibTeX
@article{Lai2023,
  author = {Lai, Timothy and Bull, Nicholas and Goonawardena, Janindu and Bradshaw, Luke and Fox, Adrian and Hassen, Sayed},
  title = {Are the screening guidelines for branch duct intraductal papillary mucinous neoplasms cost‐effective in an Australian setting?},
  journal = {ANZ Journal of Surgery},
  year = {2023},
  doi = {10.1111/ans.18697}
}
Kostenlos starten →